Research programme: ribonuclease H inhibitors - Arbutus Biopharma

Drug Profile

Research programme: ribonuclease H inhibitors - Arbutus Biopharma

Alternative Names: RNaseH inhibitors - Arbutus Biopharma

Latest Information Update: 25 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Arbutus Biopharma
  • Developer Arbutus Biopharma; Saint Louis University Liver Center
  • Class Antivirals
  • Mechanism of Action Ribonuclease H inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Hepatitis B

Most Recent Events

  • 03 May 2016 Arbutus Biopharma enters into a licensing and research collaboration agreement with Saint Louis University Liver Center for developing Ribonuclease H (RNaseH) inhibitors
  • 03 May 2016 Early research in Hepatitis B in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top